Qiagen and DiaSorin have secured approval from the US Food and Drug Administration (FDA) for the commercial launch of LIAISON QuantiFERON-TB Gold Plus (QFT-Plus) test, which enables streamlined laboratory automation for latent tuberculosis screening.

QuantiFERON-TB Plus (QFT-Plus) is a fourth-generation modern gold standard for latent tuberculosis (TB) detection that runs on DiaSorin’s LIAISON platforms.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The approval enables shifting from tuberculin skin tests to modern blood-based QuantiFERON technology.

As a result of the automated workflow on LIAISON platforms, QuantiFERON customers can have a flexible automation option for all throughput ranges.

In 2016, 10.4 million cases of active TB across the world were reported, along with 1.7 million deaths, according to WHO estimates.

In latent TB cases, the bacterium infects a person but shows no symptoms unless the disease reaches to an active stage when it becomes highly contagious.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Over 8,000 LIAISON systems have been deployed across the world so far, primarily in hospital laboratories.

Qiagen interim CEO, senior vice president and molecular diagnostics business area head Thierry Bernard said: “We are pleased to announce FDA approval of the LIAISON QuantiFERON-TB Gold Plus Test for use on the LIAISON platform and the broad-based initiation of our launch for this new automation option in the United States.

“The validation of the QuantiFERON technology with the LIAISON platforms further reinforced the clinical profile of QuantiFERON-TB Gold Plus.”

In 2017, Qiagen began collaboration with DiaSorin to develop tests for DiaSorin’s LIAISON family of analysers based on QIAGEN assay technologies.

Further tests based on QuantiFERON technology are also planned to adapt to LIAISON platforms.

Through the collaborations, customers can use Hamilton Robotics Microlab STAR automated liquid handling workstation or Tecan Fluent Laboratory Automation workstation to automate the manual process of aliquoting samples from a single collection device into QuantiFERON-TB Gold Plus tubes to carry out the analysis.